Product Description
Prednisone is a synthetic, anti-inflammatory glucocorticoid that derives from cortisone. It is biologically inert and converted to prednisolone in the liver. Prednisone is an FDA-approved, delayed-release corticosteroid indicated as an anti-inflammatory or immunosuppressive agent to treat a broad range of diseases, including immunosuppressive/endocrine, rheumatic, collagen, dermatologic, allergic states, ophthalmic, respiratory, hematologic, neoplastic, edematous, gastrointestinal, acute exacerbations of multiple sclerosis, and as an anti-inflammatory and an antineoplastic agent. (Sourced from: https://pubmed.ncbi.nlm.nih.gov/30521230/)
Mechanisms of Action: GR Agonist,Immunosuppressive
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: None *
Approval Status: Approved
Approved Countries: Algeria | Argentina | Australia | Austria | Bangladesh | Belgium | Bosnia | Brazil | Bulgaria | Canada | Chile | China | Colombia | Croatia | Cyprus | Czech | Denmark | Dominican Republic | Ecuador | Egypt | Finland | France | Germany | Hong Kong | Hungary | India | Indonesia | Ireland | Israel | Italy | Jordan | Korea | Lebanon | Lithuania | Malta | Mexico | Morocco | Netherlands | New Zealand | Pakistan | Peru | Philippines | Poland | Portugal | Romania | Russia | Saudi Arabia | Serbia | Singapore | Slovakia | Slovenia | South Africa | Spain | Sweden | Switzerland | Taiwan | Tunisia | Turkey | Ukraine | United Arab Emirates | United Kingdom | United States | Uruguay | Venezuela | Vietnam
Approved Indications: Intestinal Diseases | Renal Transplant | Transplantation Unspecified | Kidney Diseases
Known Adverse Events: Weight Gain
Company: Johnson & Johnson
Company Location: NEW BRUNSWICK NJ 08933
Company CEO: Joaquin Duato
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic: Argentina, Australia, Austria, Belarus, Belgium, Brazil, Bulgaria, Canada, Chile, China, Colombia, Croatia, Czech Republic, Denmark, Finland, France, Germany, Greece, Guatemala, Hong Kong, Hungary, India, Ireland, Israel, Italy, Japan, Korea, Latvia, Malaysia, Mexico, Netherlands, New Zealand, Norway, Peru, Poland, Portugal, Puerto Rico, Romania, Russia, Saudi Arabia, Serbia, Singapore, Slovakia, South Africa, Spain, Sweden, Switzerland, Taiwan, Thailand, Turkey, Ukraine, United Kingdom, United States, Unknown Location
Active Clinical Trial Count:
Highest Development Phases
Phase 3: Acute Lymphoid Leukemia|Asthma, Allergic|Bronchiolitis Obliterans|Conjunctivitis, Allergic|Diffuse Large B-Cell Lymphoma|Drug Hypersensitivity|Erythema Multiforme|Giant Cell Arteritis|Graft vs Host Disease|Hepatic Insufficiency|Histiocytosis|Hodgkin Lymphoma|Kidney Diseases|Kidney Failure, Chronic|Liver Transplant|Lymphoid Leukemia|Lymphoma|Lymphoma, B-Cell|Lymphoma, Non-Hodgkin|Multiple Myeloma|Other|Pemphigoid, Bullous|Polymyalgia Rheumatica|Precursor Cell Lymphoblastic Leukemia-Lymphoma|Prostate Cancer|Purpura, Thrombocytopenic, Idiopathic|Renal Transplant|Rhinitis, Allergic|T-Cell Peripheral Lymphoma|Thrombocytopenia
Phase 2: Adenocarcinoma|Allogeneic Stem Cell Transplant|COVID-19|Depressive Disorder, Major|Fetal Diseases|Follicular Lymphoma|GM1 Gangliosidosis|Gangliosidoses|Gangliosidosis, GM1|Kidney Transplant|Lung Cancer|Nose Cancer|Pneumonia|Pregnancy Complications, Infectious|Pregnancy Outcomes|Radiation Pneumonitis
Phase 1: Acute Myeloid Leukemia|B-Cell Leukemia|Blast Crisis|Chronic Lymphoid Leukemia|Chronic Myeloid Leukemia|Myelogenous, Chronic, BCR-ABL Positive Leukemia|Precursor B-Cell Lymphoblastic Leukemia-Lymphoma
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| PEACE6-Poor Responders | P3 |
Not yet recruiting |
Prostate Cancer |
2033-02-01 |
|
| CRESCENDO | P3 |
Recruiting |
T-Cell Peripheral Lymphoma |
2030-07-01 |
|
| REFRACT | P2 |
Recruiting |
Follicular Lymphoma |
2029-05-31 |
|
| CURLu177PSM0001 | P3 |
Active, not recruiting |
Prostate Cancer |
2029-02-02 |